Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus
2011

IL28B Genotype Testing for Hepatitis C Treatment

publication Evidence: moderate

Author Information

Author(s): Christine M. Nguyen, Margaret Mendes, Shirley Tsunoda, Joseph D. Ma

Primary Institution: VA San Diego Healthcare System and UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences

Hypothesis

Can IL28B genotype testing predict the response to pegylated-interferon and ribavirin in hepatitis C patients?

Conclusion

The IL28B genotype test can help identify patients more likely to respond to hepatitis C treatment.

Supporting Evidence

  • Patients with the IL28B CC genotype are more likely to achieve a sustained virologic response with treatment.
  • Only 41% and 46% of patients with HCV genotype 1 achieved SVR with peg-IFN and RBV in two clinical trials.
  • Caucasian and Hispanic patients with the CC genotype have a two-fold likelihood of achieving SVR compared to those with the TT genotype.
  • African American patients with the CC genotype have a three-fold likelihood of achieving SVR compared to the TT genotype.

Takeaway

Doctors can use a simple test to see if a patient with hepatitis C is likely to get better with certain medicines.

Methodology

The IL28B polymorphism test is a PCR analysis of a single nucleotide polymorphism on chromosome 19q13.

Limitations

The test does not account for other polymorphisms that may affect treatment response.

Participant Demographics

Among patients who achieve SVR, the frequency of CC genotype in Caucasian, Hispanics, and African Americans are 69%, 56%, and 48%, respectively.

Digital Object Identifier (DOI)

10.1371/currents.RRN1207

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication